RecruitingRecruiting
The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis
NCT07168772 · Hospital Universitari Vall d'Hebron Research Institute
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
The Effect of a Probiotic Administration as an add-on Treatment in Multiple Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial
About this study
It is a randomized, double-blind, placebo-controlled clinical trial whose general objective of this study is to determine the effects of probiotic administration in multiple sclerosis patients.
80 patients with relapsing-remitting multiple sclerosis will be enrolled in the study. Patients will be randomly assigned to receive either a probiotic (n=40) or a placebo (n=40) stratified by type of medication, gender and use of hormonal contraceptive treatment. They will receive a probiotic (Lactibane Iki) or placebo sachet twice a day for six months.
Eligibility criteria
Inclusion Criteria:
* Patients aged 18-60 years, inclusive
* Diagnosis of RRMS (McDonald Criteria 2024, Montalban et al)
* Expanded disability status scale (EDSS) score less than or equal to 5.5
* Patients receiving a first line treatment with teriflunomide, dimethyl fumarate, interferon-beta or glatiramer acetate at a stable dose, for at least 24 weeks, or patients who are not receiving treatment because they do not want to receive a disease modifying therapy after the investigator has informed them of their possible respective benefits and possible adverse events
* Not active RRMS patients (Lubin et al, 2014) for whom a switch in background therapy is not anticipated, based on the Investigator's judgment.
* At enrollment, the patient is not expected to require a change in DMT
* Females of childbearing potential must have a negative urine pregnancy test result prior to initiation of study product
* For females of childbearing potential: agreement to use adequate contraceptive methods during the treatment period
* Ability to comply with the study protocol
* Patients must sign and date a written informed consent prior to entering the study
Exclusion Criteria:
* Relapse the month before enrollment
* Use of corticosteroids the month before enrollment
* Use of antibiotics three months before enrollment
* Taking other forms of symbiotic, probiotic, prebiotic and postbiotic supplements three months before enrollment
* Patients suffering from any type of bowel disease
* Pregnant or breastfeeding or intending to become pregnant during the study.
Study design
Enrollment target: 80 participants
Allocation: randomized
Masking: triple
Age groups: adult
Timeline
Starts: 2025-07-10
Estimated completion: 2027-12-31
Last updated: 2026-08-07
Interventions
Dietary Supplement: Lactibane IkiOther: Placebo
Primary outcomes
- • Increase in the percentage of Treg cells (6 months)
Sponsor
Hospital Universitari Vall d'Hebron Research Institute · other
All locations (1)
Centre d'Esclerosi Mútiple de Catalunya (Cemcat)Recruiting
Barcelona, Barcelona, Spain